A Randomized Phase II Study of Rituximab With ABVD Versus Standard ABVD for Patients With Advanced-Stage Classical Hodgkin Lymphoma With Poor Risk Features (IPS Score > 2).
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2018
At a glance
- Drugs Bleomycin (Primary) ; Dacarbazine (Primary) ; Doxorubicin (Primary) ; Rituximab (Primary) ; Vinblastine (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 18 Sep 2018 Planned End Date changed from 1 Mar 2020 to 31 Mar 2020.
- 18 Sep 2018 Planned primary completion date changed from 1 Mar 2019 to 31 Mar 2019.
- 16 Sep 2018 Status changed from active, no longer recruiting to completed.